Cancer patients are set to benefit from a new agreement between a Brisbane company developing ground-breaking nanodiagnostic technologies and the world’s leading genomics organisation.
XING Technologies Pty Ltd – a spinoff from the University of Queensland - has signed a Memorandum of Understanding (MoU) with BGI - headquartered in China - to deliver its cutting-edge technology in the field of personalized healthcare.
XING CEO Tom Esplin said the company was partnering with BGI to help expedite the application of these nanotechnologies and to make them accessible to patients with cancer and other diseases.
“BGI are a major global player revolutionizing healthcare,” said Mr Esplin.
“Together we aim to bring rapid, affordable nanodiagnostics to the whole world, not just the fortunate few.”
XING’s Chief Medical Officer Dr Paul Mainwaring said XING’s disruptive nanotechnology was ground-breaking in that it would enable rapid, point-of-care diagnosis, screening and ongoing monitoring of cancer without requiring access to laboratory facilities and highly trained personnel.
This technology is particularly applicable to developing nations who lack the medical infrastructure and public funding to provide a standard of healthcare that is taken for granted in Australia.
A sample of the patient’s urine, sputum or blood is inserted into XING’s cartridge and analysed via its portable reader right there and then. Results are transmitted to a cloud software platform and a report is then transmitted back to the doctor, nurse or healthcare worker.
The system leverages XING's “Laboratory-in-a-drop” technology, and could potentially be used to accurately, rapidly, and inexpensively screen and monitor diseases in different applications, including human health, veterinary, agriculture, aquaculture and food safety.
The company plans to establish global manufacturing of the system in Brisbane.
The MoU with BGI will initially target specific diseases which are common throughout the pan-Asian region. This coincides with a global launch of the platform technology known as the ‘Genosis’ system at a major diagnostics conference in Washington DC, last week.
XING has recently established headquarters and laboratory facilities at Sinnamon Park. In addition to its innovative point-of-care diagnostic technology, XING plans to offer in the near future advanced genetic sequencing services to cancer patients in the pan-Asian region.
“We see ourselves as a global company with particular focus on the pan-Asian region. Whilst we are located in Brisbane, our vision is much larger than Australia,” said Mr Esplin.
Dr Mainwaring and XING co-founder the University of Queensland’s Chemistry Professor and Centre for Personalised Nanomedicine director Matt Trau said ultimately the collaboration meant better outcomes for cancer patients.
“BGI and XING share a common vision aiming to improve health outcomes for people around the world,” said Dr Mainwaring.
Dr Mainwaring and Professor Trau consider cancer to be the greatest challenge of our time and established XING in 2013 because cancer diagnosis and treatment was developing a need for “new tools”.
As part of the collaboration, MGI, a subsidiary corporation of BGI, has deployed its BGISEQ-500 NGS sequencer at XING’s laboratory in Brisbane.
About XING Technologies
XING is a spin-out company specializing in world-leading disease diagnosis and monitoring technologies, including cancer. Its proprietary nanotechnologies are transforming the future practice of medicine and healthcare. These include nanotechnologies for nucleic acid, protein and rare cell detection. The company has concluded a Series A investment round, successful deals with national and international companies and is currently growing its operations.
BGI, known as the Beijing Genomics Institute prior to 2008, is the largest gen-sequencing facility in the world, headquartered in Shenzhen, Guangdong, China.
Since the BGI Australia office opened in 2016, BGI has initiated partnership projects covering with strong local scientific research partners, such as imaging and genomics cancer, infectious disease, marine biology, and biodiversity.